Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients

Clinical Cancer Research

Volumn 3, Issue 10, 1997, Pages 1815-1822

  Kos, Janko ^a,c   Štabuc, Borut ^b   Schweiger, Ana ^a   Krašovec, Marta ^c   Cimerman, Nina ^c   Kopitar Jerala, Nataša ^a   Vrhovec, Ivan ^b  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

^c Krka   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; CATHEPSIN H; CATHEPSIN L; CYSTATIN C; STEFIN A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MALE; MELANOMA; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; SERODIAGNOSIS;

ADULT; AGED; CATHEPSIN B; CATHEPSIN H; CATHEPSIN L; CATHEPSINS; CYSTATIN A; CYSTATIN C; CYSTATINS; CYSTEINE ENDOPEPTIDASES; ENDOPEPTIDASES; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIFE TABLES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0030796705     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Duffy, M. J. Proteases as prognostic markers in cancer. Clin. Cancer Res., 2: 613-618, 1996.
2. Schmitt, M., Janicke, F., and Graeff, F. Tumor-associated proteases. Fibrinolysis, 6 (Suppl. 4): 3-26, 1992.
3. Sloane, B. F., Moin, K., and Lah, T. T. Regulation of lysosomal endopeptidases in malignant neoplasia. In: T. G. Pretlow and T. P. Pretlow (eds.), Biochemical and Molecular Aspects of Selected Cancers, pp. 411-472. New York: Academic Press, 1994.
4. Lah, T. T., Buck, M. R., Bonn, K. V., Crissman, J. D., Rao, N. C., Liotta, L. A., and Sloane, B. F. Degradation of laminin by human tumour cathepsin B. Clin. Exp. Metastasis, 7: 461-468, 1989.
5. Uchiyama, Y., Waguri, S., Sato, N., Watanabe, T., Ishido, K., and Kominami, E. Cell and tissue distribution of lysosomal cysteine proteinases, cathepsins B, H and L, and their biological roles. Acta Histochem. Cytochem., 27: 287-308, 1994.
6. Turk, V., and Bode, W. Human cysteine proteinases and their inhibitors, stefins and cystatins. In: F. X. Aviles (ed.), Innovations in Proteases and Their Inhibitors, pp. 47-59. Berlin: W. de Gruyter, 1993.
7. Thomssen, C., Schmitt, M., Goretzki, L., Oppelt, P., Janicke, F., Pache, L., and Graeff, H. Prognostic value of the cysteine proteases cathepsin B and L in human breast cancer. Clin. Cancer Res., 1: 741-746, 1995.
8. Budihna, M., Strojan, P., Šmid, L., Škrk, J., Vrhovec, I., Župevc, A., Rudolf, Z., Žargi, M., Krašovec, M., Svetic, B., Kopitar-Jerala, N., and Kos, J. Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol. Chem. Hoppe-Seyler, 377: 385-390, 1996.
9. Campo, E., Munoz, J., Miquel, R., Palacin, A., Cardesa, A., Sloane, B. F., and Emmeret-Buck, M. R. Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am. J. Pathol., 145: 301-309, 1994.
10. Sukoh, N., Abe, S., Ogura, S., Isobe, H., Takekawa, H., Inoue, K., and Kawakami, Y. Immunochemical study of cathepsin B. Cancer (Phila.), 74: 46-51, 1994.
11. Ebert, W., Knoch, H., Werle, B., Trefz, G., Muley, T. H., and Spiess, E. Prognostic value of increased lung tumor tissue cathepsin B. Anticancer Res., 14: 895-900, 1994.
12. Knoch, H., Werle, B., Ebert, W., and Spiess, E. Imbalance between cathepsin B and cysteine proteinase inhibitors is of prognostic significance in human lung cancer. Int. J. Oncol., 5: 77-85, 1994.
13. Werle, B., Ebert, W., Klein, W., and Spiess, E. Cathepsin B in tumours, normal tissue and isolated cells from human lung. Anticancer Res., 14: 1169-1176, 1994.
14. Siewinski, M., Krecicki, T., Jarmulowicz, J., and Berdowska, I. Cysteine proteinase inhibitors in serum of patients with head and neck tumours. Diagn. Oncol., 2: 323-326, 1992.
15. Lah, T. T., Kokalj-Kunovar, M., Kastelic, L., Babnik, J., Stolfa, A., Rainer, S., and Turk, V. Cystatins and stefins in ascites fluid from ovarian carcinoma. Cancer Lett., 61: 243-253, 1991.
16. Siewinski, M., Gutowicz, J., Kielan, W., and Bolanowski, M. Cysteine peptidase inhibitors and activators in urine of patients with colorectal cancer. Oncology, 51: 446-449, 1994.
17. Gabrijelčič, D., Svetic, B., Spaić, D., Škrk, J., Budihna, M., Dolenc, I., Popović, T., Cotič, V., and Turk, V. Cathepsins B, H, and L in human breast carcinoma. Eur. J. Clin. Chem. Clin. Biochem., 30: 69-74, 1992.
18. Tumminello, F. M., Pizzolanti, G., Gebbia, N., and Leto, G. Stefin A and cathepsin B and L circulating serum levels in patients with malignant or non-malignant liver diseases: a preliminary report. Med. Sci. Res., 23: 741-742, 1995.
19. Leto, G., Tumminello, F. M., Pizzolanti, G., Montalto, G., Soresi, M., Carroccio, A., Ippolito, S., and Gebbia, N. Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis. Pancreas, 14: 22-27, 1997.
20. Luthgens, K., Ebert, W., Treftz, G., Gabrijelčič, D., Turk, V., and Lah, T. Cathepsin B and cysteine proteinase inhibitor in bronchoalveolar fluid of lung cancer patients. Cancer Prev. Detect, 17: 387-397, 1993.
21. Rudolf, Z., and Roš-Opaškar, T. Survival and disease-free interval of malignant melanoma patients in relation to the prognostic factors. Radiol Oncol., 26: 45-55, 1992.
22. Sirott, M. N., Bajorin, D. F., and Wong, G. Y. Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis. Cancer (Phila.) 72: 3091-3098, 1993.
23. Wibe, E., Hannisdal, E., Paus, E., and Aamdal, S. Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma. Eur. J. Cancer, 28A: 1692-1695, 1992.
24. Kageshita, T., Yoshii, A., Kimura, T., Maruo, K., Ono, T., Himeno, M., and Nishimura, Y. Biochemical and immunohistochemical analysis of cathepsins B, H, L and D in Human melanocytic tumors. Arch. Dermatol. Res., 287: 266-272, 1995.
25. Stabuc, B., Rudolf, Z., Kotnik, V., and Zakotnik, B. Treatment of metastatic melanoma with interferon α-2b and combination chemotherapy. Eur. J. Cancer 29A (Suppl. 6): 181, 1993.
26. Popović, T., Brzin, J., Kos, J., Lenarčič, B., Machleidt, W., Ritonja, A., Hanada, K., and Turk, V. A new purification procedure of human kidney cathepsin H, its properties and kinetic data. Biol. Chem. Hoppe-Seyler, 371: 575-580, 1988.
27. Jerala, R., Žerovnik, E., Lohner, K., and Turk, V. Structural basis for the difference in thermodynamic properties between the two cysteine proteinase inhibitors human stefins A and B. Protein Eng., 7: 977-984, 1994.
28. Cimerman, N. Preparation of some recombinant human cystatin C mutants and their characterisation (Ph.D. Thesis), Ljubljana, Slovenia: University of Ljubljana, 1993.
29. Kos, J., Šmid, L., Krašovec, M., Svetic, B., Lenarčič, B., Vrhovec, I., Škrk, J., and Turk, V. Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol. Chem. Hoppe-Seyler, 376: 401-405, 1995.
30. Schweiger, A., Štabuc, B., Popovič, T., and Kos, J. Enzyme-linked immunosorbent assay for the detection of total cathepsin H in human tissue cytosols and sera. J. Immunol. Methods, 201: 165-172, 1997.
31. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc., 53: 457-481, 1958.
32. Cox, D. R. Regression models and life tables (with discussion). J. R. Stat. Soc., 187: 187-220, 1972.
33. Breslow, A. Tumor thickness level of invasion and node dissection in stage I cutaneous melanoma. Ann. Surg., 182: 5-10, 1975.
34. Clark, W. H. The developmental biology of primary human malignant melanoma. Oncology, 3: 82-87, 1975.
35. Vollmer, R. T. Malignant melanoma: a multivariate analysis of prognostic factors. Pathol. Annu., 24: 383-407, 1989.
36. Balch, C. M., Houghton, A., and Peters, L. Cutaneous melanoma. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer Principles and Practice of Oncology, pp. 1499-1542. Philadelphia, J. B. Lippincott, 1989.
37. Graeff, H., Harbeck, N., Pache, L., Wilhem, O., Janicke, F., and Schmitt, M. Prognostic impact and clinical relevance of tumor-associated proteases in breast cancer. Fibrinolysis 6 (Suppl. 4): 45-53, 1992.
38. Lah, T. T., Kokalj-Kunovar, M., Štrukelj, B., Pungerčar, J., Magajna, D., Drobnič-Košorok, M., Kastelic, L., Babnik, J., Golouh, R., and Turk, V. Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int. J. Cancer 50: 36-44, 1992.
39. Lah, T. T., Clifford, J. L., Helmer, K. M., Day, N. A., Moin, K., Honn, K. V., Crissman, J. D., and Sloane, B. F. Inhibitory properties of low-molecular-mass cysteine proteinase inhibitors from human sarcoma. Biochem. Biophys. Acta, 993: 63-73, 1989.
40. Starkely, P. M., Fletcher, T. C., and Barrett, A. J. Evolution of α2-macroglobulin. The purification and characterisation of protein homologous with human α2-macroglobulin from plaice (Pleuromides platessa) plasma. Biochem. J., 205: 97-104, 1982.
41. Rozhin, J., Robinson, D., Stevens, M. A., Lah, T. T., Honn, K. V., Ryan, R. E., and Sloane, B. F. Properties of plasma membrane associated cathepsin B-like cysteine proteinase in metastatic B 16a melanoma variants. Cancer Res., 47: 6620-6628, 1987.
42. Boike, G., Lah, T., Sloane, B. F., Rozhin, J., Honn, K., Guirguis, R., Stracke, M. L., Liotta, L. A., and Schiffman, E. A possible role for cysteine proteinase and its inhibitors in motility of malignant melanoma and other tumour cells. Melanoma Res., 1: 333-340, 1991.
43. Rozhin, J., Wade, R. L., Honn, K. V., and Sloane, B. F. Membrane-associated cathepsin L: a role in metastasis of melanomas. Biochem. Biophys. Res. Commun., 164: 556-561, 1989.
44. Tsushima, H., Ueki, A., Matsuoka, Y., Mihara, H., and Hopsu-Havu, V. K. Characterisation of cathepsin-H-like enzyme from a human melanoma cell line. Int. J. Cancer, 48: 726-732, 1991.
45. Chauhan, S. S., Goldstein, L. J., and Gottesmann, M. M. Expression of cathepsin L in human tumours. Cancer Res., 51: 1478-1481, 1991.
46. Jarvinen, M., Rinne, A., and Hopsu-Havu, V. K. Human cystatins in normal and diseased tissues: a review. Acta Histochem., 82: 5-18, 1987.
47. Heskens, Y. M. C., Veerman, E. C. I., and Nieuw Amerongen, A. V. Cystatins in health and disease. Biol. Chem. Hoppe-Seyler, 377: 71-86, 1996.
48. Jung, K., Nowak, L., Lein, M., Preim, F., Schnorr, D., and Loening, S. A. Matrix metalloproteinases 1 and 3, tissue inhibitors of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer. Int. J. Cancer, 74: 220-223, 1997.
49. Nielsen, H. J., Pappot, H., Christensen, I. J., Brunner, N., Ussing, O. T., Moesgaard, F., Dano, K., and Grondahl-Hansen, J. Association between plasma PAI-1 level and survival in patients with colorectal cancer. Br. Med. J., in press, 1997.
50. Newman, D. J., Thakkar, H., Edwards, R. G., Wilkie, M., White, T., Grubb, A. O., and Price, C. P. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes of GFR than serum creatinine. Kidney Int., 47: 312-318, 1995.
51. Ledakis, P., Tester, W. T., Rosenberg, N., Romero-Fischmann, D., Daskal, I., and Lah, T. T. Cathepsins D, B, and L in malignant human lung tissue. Clin. Cancer Res., 2: 561-568, 1996.